-
1.
公开(公告)号:US20190240327A9
公开(公告)日:2019-08-08
申请号:US14075566
申请日:2013-11-08
发明人: Hong Yu , Drew M. Pardoll , Xiaoyu Pan , Charles G. Drake , Jonathan D. Powell , Ching-Tai Huang , Joseph Barbi , Fan Pan
IPC分类号: A61K39/395 , A61K35/14 , A61K31/713 , A61K39/00
CPC分类号: A61K39/39558 , A01K67/0275 , A01K67/0276 , A01K2217/052 , A01K2217/075 , A01K2217/206 , A01K2227/105 , A01K2267/0387 , A61K31/713 , A61K35/17 , A61K38/18 , A61K39/0011 , A61K45/06 , C07K14/475 , C07K16/22 , C07K2319/30
摘要: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.
-
公开(公告)号:US20190240208A1
公开(公告)日:2019-08-08
申请号:US16124407
申请日:2018-09-07
IPC分类号: A61K31/4439 , A61K47/26 , A61K9/00 , A61K9/10 , A61K47/38 , A61K45/06 , A61K47/12 , A61M37/00 , A61K9/16 , C07K16/22 , A61K31/573
CPC分类号: A61K31/4439 , A61K9/0019 , A61K9/0048 , A61K9/10 , A61K9/16 , A61K31/573 , A61K45/06 , A61K47/12 , A61K47/26 , A61K47/38 , A61K2039/505 , A61K2039/54 , A61K2300/00 , A61M37/0015 , A61M2037/0023 , A61M2037/0061 , C07K16/22
摘要: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
-
公开(公告)号:US20190233517A1
公开(公告)日:2019-08-01
申请号:US16075922
申请日:2017-02-06
发明人: Chengbin WU
IPC分类号: C07K16/28 , C07K16/22 , C07K16/24 , C07K16/32 , C07K16/36 , A61P35/00 , A61P25/28 , A61P37/06 , A61P29/00
CPC分类号: C07K16/2818 , A61K39/395 , A61K2039/505 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/06 , C07K16/18 , C07K16/22 , C07K16/241 , C07K16/244 , C07K16/2803 , C07K16/2809 , C07K16/2827 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K16/36 , C07K2317/14 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.
-
公开(公告)号:US20190218298A1
公开(公告)日:2019-07-18
申请号:US16331902
申请日:2017-09-29
发明人: Stephen L. NISHIMURA , Jianlong LOU , James D. MARKS , Jody L. BARON , Yifan CHENG , Shenping WU , Anthony CORMIER , Naoki TAKASAKA
IPC分类号: C07K16/28 , C07K16/22 , C07K14/705 , A61P31/20 , A61P37/04 , A61P35/04 , G01N33/563 , A61P1/04
CPC分类号: C07K16/2839 , A61K2039/505 , A61P1/04 , A61P31/20 , A61P35/04 , A61P37/04 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/622 , C07K2317/76 , C07K2317/92 , G01N33/563
摘要: Provided is an antibody that specifically binds human αvββ and blocks binding of TGFp peptide to αvβ8, wherein the antibody binds to the specificity determining loop (SDL) of human β8. In some embodiments, the antibody further binds to one, two, or all three of the human av-head domain, the al helix of human β8, or the al helix of human β8. In some embodiments, the antibody is humanized or chimeric. In some embodiments, the antibody is linked to a detectable label. Also provided is a method of enhancing an immune response in a human individual, comprising administering a sufficient amount of the antibody to the individual, thereby enhancing an immune response. Also provided are pharmaceutical compositions comprising the anti-αvββ antibodies or antigen-binding molecules thereof.
-
公开(公告)号:US20180346602A1
公开(公告)日:2018-12-06
申请号:US15962429
申请日:2018-04-25
CPC分类号: C07K16/22 , C07K16/00 , C07K16/283 , C07K16/2854 , C07K16/2863 , C07K16/42 , C07K2317/524 , C07K2317/526
摘要: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.
-
公开(公告)号:US20180327487A1
公开(公告)日:2018-11-15
申请号:US15977449
申请日:2018-05-11
申请人: argenx BVBA
发明人: Sebastian Van der Woning , Filip Borgions , Torsten Dreier , Lore Mariën , Federica Linty , Gitte De Boeck , Hans De Haard , Stéphanie Liénart , Sophie Lucas , Pierre Coulie , Michael Saunders
CPC分类号: C07K16/22 , A61K2039/505 , C07K16/28 , C07K2317/22 , C07K2317/32 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
-
公开(公告)号:US20180325992A1
公开(公告)日:2018-11-15
申请号:US15908024
申请日:2018-02-28
申请人: Genentech, Inc.
发明人: Ryan J. WATTS , Mark CHEN , Joseph Wesley LEWCOCK , Christine POZNIAK , Arundhati SENGUPTA-GHOSH
IPC分类号: A61K38/12 , A61K31/711 , A61K31/7105 , C12N15/113 , A61K31/40 , A61K31/426 , A61K31/433 , A61K31/45 , A61K31/496 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/713 , C07K16/40 , A61K31/12 , A61K31/165 , A61K31/352 , A61K31/4184 , A61K31/277 , A61K31/35 , A61K31/4015 , A61K31/416 , A61K31/4439 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K33/14 , A61K38/05 , A61K38/18 , C07K16/22 , G01N33/50 , A61K31/7088
CPC分类号: A61K38/12 , A61K31/12 , A61K31/165 , A61K31/277 , A61K31/35 , A61K31/352 , A61K31/40 , A61K31/4015 , A61K31/416 , A61K31/4184 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/45 , A61K31/496 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/713 , A61K33/14 , A61K38/05 , A61K38/185 , C07K16/22 , C07K16/40 , C07K2317/76 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2320/30 , G01N33/5058
摘要: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
-
8.
公开(公告)号:US20180319877A1
公开(公告)日:2018-11-08
申请号:US15963455
申请日:2018-04-26
发明人: Yoshinao RUIKE , Taichi KURAMOCHI , Hiroyasu MURAMATSU , Atsunori UEYAMA , Tomoyuki IGAWA , Hitoshi KATADA , Yuji HORI
CPC分类号: C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N2510/02 , G01N33/6872 , G01N2333/495
摘要: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
-
公开(公告)号:US20180319875A1
公开(公告)日:2018-11-08
申请号:US15895771
申请日:2018-02-13
申请人: Menotti Ruvo , Annamaria Sandomenico , Antonio Leonardi , Luca Sanguigno , ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO
发明人: Menotti Ruvo , Annamaria Sandomenico , Antonio Leonardi , Luca Sanguigno , Mary J.C. Hendrix , Elisabeth A. Seftor , Richard E.B. Seftor , Luigi Strizzi , Zhila Khalkhali-Ellis
IPC分类号: C07K16/22 , A61K39/395 , C12N15/113 , A61K31/655 , G01N33/68 , A61K39/00
CPC分类号: C07K16/22 , A61K31/655 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/1136 , G01N33/6863 , G01N2800/7028 , A61K2300/00
摘要: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.
-
公开(公告)号:US20180312582A1
公开(公告)日:2018-11-01
申请号:US16026397
申请日:2018-07-03
申请人: Ascendis Pharma A/S
发明人: Harald Rau , Nicola Bisek , Thomas Knappe , Romy Reimann , Sebastian Stark , Samuel Weisbrod
CPC分类号: C07K16/22 , A61K47/543 , A61K47/641 , A61K47/645 , C07K1/1075 , C07K1/18 , C07K2317/24 , C07K2317/55 , Y02P20/55
摘要: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.
-
-
-
-
-
-
-
-
-